Guggenheim lowered the firm’s price target on Compass Therapeutics (CMPX) to $10 from $12 and keeps a Buy rating on the shares. After the quarterly report, the firm updated its model to account for Q1 results and refined launch timing assumptions for tovecimig, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics Reports Q1 2025 Financial Results
- Compass Therapeutics reports Q1 EPS (12c), consensus (11c)
- Compass Therapeutics has anticipated cash runway into 2027
- Compass Therapeutics presents data on efficacy of CTX-471
- Compass Therapeutics’ Tovecimig Shows Promise in BTC Treatment, Supporting Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue